Navigation Links
Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons

Company Announces Extension of Phase I/IIa Trial to 9 mg Dosage Level

HOPKINTON, Mass., April 16, 2007 /PRNewswire-FirstCall/ -- Boston Life Sciences announced today that clinical data on its lead nerve repair therapy, Cethrin(R), were presented in the Neurotrauma and Critical Care Scientific Session at the 75th Annual Meeting of the American Association of Neurological Surgeons (AANS) in Washington, DC.

The oral presentation, "Results of the Cethrin Phase I/IIa Prospective Clinical Trial of a Rho Inhibitor for the Treatment of Acute Spinal Cord Injury," was given by Michael G. Fehlings, MD, PhD, FRC, Medical Director of the Krembil Neuroscience Center and Head of the Spinal Program at the University Health Network of the University of Toronto and principle investigator in the study. Co-authors are Nicholas Theodore, MD, James Harrop, MD, Gilles Maurais, MD, Charles Kuntz, MD, Christopher Shaffrey, MD, Brian Kwon, MD, Jens Chapman, MD, Albert Yee, MD, Patrick Tremblay, PhD, and Lisa McKerracher, PhD.

"The preliminary results in this study show that Cethrin may offer great promise for restoring sensory and motor function for patients with new cases of acute SCI," stated Dr. Mark Hurtt, BLSI's Chief Medical Officer. "We have extended the Phase IIa trial to include a 9 mg dose. Currently, three patients have been enrolled at this level and we expect the enrollment at this dosage extension to continue to the 3rd quarter of 2007. Additionally, based on the positive findings to-date in the Phase I/II trial, we are drafting a protocol for a Phase IIb/III study. We plan to meet with the FDA and with Health Canada and plan to initiate this trial in North America by the end of this year or early 2008."

Thirty-seven patients with acute SCI were enrolled in the open label study at nine sites across Canada and the United States. All patients were classified with a complete SCI assessed as American Spina
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/27/2014)... Aug. 28, 2014 China Nepstar Chain ... the "Company"), a leading retail drugstore chain in ... stores, today announced its unaudited financial results for ... Financial HighlightsFor the quarter ended June 30, 2014: ... million) compared to RMB638.8 million in the second ...
(Date:8/27/2014)... , Aug. 27, 2014 TWi Pharmaceuticals, ... approval from the United States Food and Drug ... (ANDA) for megestrol acetate 125mg/ml oral suspension, the ... is the first-to-file and under Hatch Waxman rules, ... marketing exclusivity.  TWi has completed the pre-launch preparation ...
(Date:8/27/2014)... 27, 2014 Reportbuyer.com has added ... Collaborative R&D Terms & Agreements in Pharma, ... The Collaborative R&D Terms and ... provides comprehensive understanding and unprecedented access to ... into by the worlds leading life science ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2014 Financial Results 11TWi Pharmaceuticals Receives US FDA Final Approval on Generic Megestrol Acetate 125mg/ml Oral Suspension 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9
... Mylan Inc. (Nasdaq: MYL ) today ... final approval from the U.S. Food and Drug Administration ... Ibandronate Sodium Tablets, 150mg. This product is the generic ... treatment and prevention of osteoporosis in postmenopausal women. ...
... YORK, March 20, 2012 Reportlinker.com ... report is available in its catalogue: ... Market: Western Europe Market Size, Segment ... http://www.reportlinker.com/p0797078/Nutraceuticals-Product-Market-Western-Europe-Market-Size-Segment-And-Country-Analysis-And-Forecasts-2007-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nutraceutical ...
Cached Medicine Technology:Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 2Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 3Nutraceuticals Product Market: Western Europe Market Size, Segment And Country Analysis And Forecasts (2007-2017) 4
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 On ... its annual CombFirst! Back-to-School campaign. The goal is ... control head lice calmly and effectively and without exposures ... Academy of Pediatrics agree: “Children’s exposures to pesticides ... http://pediatrics.aappublications.org/content/130/6/e1765.full , Head lice are often trivialized ...
(Date:8/27/2014)... Louis, Missouri (PRWEB) August 28, 2014 ... Carey Danis & Lowe reports that the ... comprised of thousands of consolidated transvaginal mesh lawsuits, recently ... 2014.* PTO #136 pertains to the pretrial discovery process, ... of physically sensitive evidence. , Carey Danis & Lowe ...
(Date:8/27/2014)... Fort Lauderdale, FL (PRWEB) August 27, 2014 ... of cost-effective money-saving dental plans, has launched in ... and consumers access to quality, affordable dental care ... a leading destination for Tennessee consumers looking to ... accessing reduced-fee dental rates as a member of ...
(Date:8/27/2014)... For those who want to build dynamic ... are very practical. Top10BestSEOHosting.com today announces that Hostgator ... best ASP.NET hosting suppliers of this year. ... web hosting provider for a long time, and ... Recently proclaimed one of the fastest growing web ...
(Date:8/27/2014)... August 27, 2014 Philadelphia, PA. ... 33rd annual Inc. 500 list, an exclusive ranking of ... the most comprehensive look at the most important segment ... companies who gained early exposure as members of the ... Domino’s Pizza. , “Some of world’s greatest companies ...
Breaking Medicine News(10 mins):Health News:Head Lice Can Be a Public Health Opportunity 2Health News:Head Lice Can Be a Public Health Opportunity 3Health News:Head Lice Can Be a Public Health Opportunity 4Health News:Carey Danis & Lowe Reports On New Court Order in C.R. Bard Transvaginal Mesh MDL 2Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 2Health News:DentistSave.com Launches Discount Dental Plans in Tennessee for Consumers, Businesses, and Groups 3Health News:Top10BestSEOHosting.com Releases the Best ASP.NET Hosting Suppliers of This Year: Hostgator, Arvixe and FatCow 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2
... and its partner Hyderabad-based Biological E. Ltd. announced ... a pediatric phase II clinical trial for Intercell’s ... ,The randomized and controlled study aims to demonstrate ... vaccine compared to a locally produced mouse-brain Japanese ...
... the U.S. population. Nearly one-third of affected people have ... do not work well. Those who suffer from it ... biofeedback treatment can successfully retrain muscles. ,The biofeedback ... and exercise or another treatment (sham) that included muscle ...
... Responding to calls for a fair distribution of bird ... to create a global stockpile of vaccines// for developing ... great importance in the fight against avian influenza, WHO ... The Jakarta Post Thursday. ,Chan met President ...
... and Wales have been accused of being institutionally racist. ... although services are pioneers in moving towards equity, they ... challenges of a multi-cultural society. ,The "Count ... Commission, makes grim reading for people of African and ...
... during a recent influenza B epidemic in Japan showed ... drugs//, according to a study. ,Two antiviral ... drugs known as neuraminidase inhibitors, have been effective against ... evidence of the emergence of oseltamivir-resistant type A viruses, ...
... ruling in Alberta empowers pharmacists to prescribe medicines to ... will be allowed to take a decision on the ... or prescriptions given by doctors. ,Though this ... about the ability of the pharmacists to diagnose medical ...
Cached Medicine News:Health News:Biofeedback Treats One Type Of Chronic Constipation 2Health News:Biofeedback Treats One Type Of Chronic Constipation 3Health News:Chances of Tackling Racism in Mental Health Care is Still Remote 2Health News:Study Suggests Some Drug Resistance to Influenza B Medications 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
18 gauge straight. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Medicine Products: